Benzoyl Peroxide for Rosacea: What It Clears, and What It Never Touches

Marina Ivakhnenko

August 25, 2026

Clinical Trials, Demodex & Acne, Demodex & Facial Folliculitis, Demodex & Folliculitis, Demodex & Refractory Acne, Demodex & Rosacea, Demodex & Seborrheic Dermatitis, DEMODEX & SKIN CONDITIONS, Demodex vs Fungal Acne, Dermatology Studies, Differential Diagnosis, Facial Seb Derm, New Treatments, Papulopustular Rosacea, Research & Clinical Studies, RESEARCH & SCIENCE, TESTING & DIAGNOSIS, Topical Therapies, TREATMENT & PROTOCOLS, Treatment Protocols

Benzoyl peroxide for rosacea title card with three key trial statistics

You were probably told to keep benzoyl peroxide away from your face. Most people with
rosacea were, and for thirty years the advice against benzoyl peroxide for rosacea was close to
universal. It was the acne ingredient: the one that stripped and stung and turned pillowcases
white.

Then a reformulated version went through two phase 3 trials, passed, and the advice quietly
changed. If you have been flaring on and off for years and someone has just handed you a
prescription for it, you are entitled to ask what actually changed.

The honest answer is that the molecule did not change. The delivery changed.
That distinction turns out to explain almost everything about what this drug does for you and
what it will leave exactly where it was.

Quick answer

Benzoyl peroxide for rosacea works, but only on one part of the problem. A
microencapsulated 5% cream cleared or almost cleared 43.5% and 50.1% of patients in two phase 3
trials, against 16.1% and 25.9% on the vehicle cream alone. It reduces papules and pustules. It
has no published effect on Demodex mite density, because no study has counted
mites before and after treatment. It does not reduce background redness or visible vessels.
Plain over-the-counter benzoyl peroxide is a different product from the encapsulated
prescription cream and has never been tested head to head against it in rosacea.

733patients across the two phase 3 trials of encapsulated benzoyl peroxide
25.9%cleared or almost cleared on the vehicle cream with no active drug in it
0published studies measuring mite density before and after benzoyl peroxide

What benzoyl peroxide for rosacea actually does to the skin

Benzoyl peroxide is an oxidising agent. When it meets skin it breaks down and
releases free radicals that damage the membranes and proteins of surface organisms. It is not an
antibiotic and organisms do not develop resistance to it, which is why dermatology has kept
reaching for it since the 1960s.

It is also mildly keratolytic. It loosens the plug of dead cells and hardened
oil at the mouth of the follicle. In acne that matters a great deal, because the plug is where
the disease starts.

Neither of those two actions is aimed at a mite. Keep that in mind, because it is the thread
running through the rest of this article: benzoyl peroxide for rosacea was developed against
bacteria and follicular plugging, and it has never been redesigned around an arachnid.

Four step rosacea cascade diagram showing where benzoyl peroxide for rosacea acts
Benzoyl peroxide enters the cascade at the microbial and inflammatory steps. It does not enter at step 1, and it cannot reverse step 4.

Why benzoyl peroxide for rosacea was avoided for thirty years

Rosacea-prone skin is not acne-prone skin wearing a different name. Measured against healthy
controls, skin in papulopustular rosacea has lower water content in the outer layer, lower
surface lipid and higher water loss through the barrier. It is a damaged barrier
carrying an inflammatory disease.

Drop a strong oxidiser onto that and you get stinging, scaling and a flare. This is not a myth
dermatology invented. It is what happened to a generation of patients handed acne products for a
rosacea diagnosis, and it is the pattern described in our guide to
rough, sandpapery skin texture.

The reformulation exists to solve exactly this. The active is locked inside
silica microcapsules that sit on the skin and release the drug slowly, so the
peak concentration hitting any one point of the barrier is lower. Same molecule, gentler arrival.

That is the whole reason benzoyl peroxide for rosacea became prescribable at all. Nothing about
the chemistry was improved. The rate of delivery was.

What the phase 3 trials of benzoyl peroxide for rosacea showed

Two 12-week, randomised, double-blind, vehicle-controlled trials enrolled 733 adults with
moderate to severe rosacea, randomised two to one to once-daily encapsulated 5% cream or to the
vehicle cream. The results were published in 2023 and are
available in full.

In study 1, 43.5% of patients were rated clear or almost clear at week 12,
against 16.1% on vehicle. In study 2 the figures were 50.1% and 25.9%.
Inflammatory lesion counts fell by 17.4 and 20.3 on the drug, against 9.5 and 13.3 on vehicle.
All of those differences were significant, and the separation from vehicle was already visible at
week 2.

A 40-week open-label extension of benzoyl peroxide for rosacea followed. Patients continuing on the active cream were at
67.6% clear or almost clear, and patients switched over from the vehicle arm reached 66.5%. In
other words the curve was still climbing well past the 12-week mark, which is a pattern we also
see with sub-antimicrobial doxycycline.

Bar chart of benzoyl peroxide for rosacea phase 3 IGA success rates versus vehicle
Drug beats vehicle in both trials. The vehicle result is the number to keep in mind when judging any product you try at home.

The number that never makes the leaflet

Look again at study 2. A quarter of patients cleared or almost cleared on a cream with
no active drug in it.
That is not a fluke and it is not a trick of statistics. It is the
combination of a moisturising base, a simplified routine, the removal of whatever people were
using before, and the natural fluctuation of a relapsing disease.

This single number should change how you judge every product you have ever tried at home. If
you start something new and improve, roughly a quarter of that improvement would have happened
with a plain cream.

It is also the reason a two-week win means very little and a twelve-week win means something.
When you assess benzoyl peroxide for rosacea on yourself, you are assessing it against that
quarter, not against nothing.

The comparison nobody ran

Here is the limitation the trial authors state plainly and almost nobody repeats: the
encapsulated cream was never compared with unencapsulated benzoyl peroxide.

So the trials prove the finished product beats a placebo cream. They do not prove the
microcapsule is what made the difference, and they do not tell you what would have happened with
a cheap 5% gel from a pharmacy shelf. The tolerability data look reassuring, with only 1.8% of
patients stopping for side effects against 0.4% on vehicle, but reassuring against vehicle is not
the same as proven gentler than the old formulation.

Does benzoyl peroxide for rosacea reduce Demodex mites?

This is the question we get asked most, and the answer is unusually clean:
nobody knows, because nobody has measured it.

There is no published trial, case series or in-vitro study reporting Demodex counts before and
after benzoyl peroxide. The phase 3 programme did not sample mites. That is not a criticism of the
trials, which were designed to answer a different question, but it does mean that any claim you
read online about benzoyl peroxide for rosacea clearing mites is an
extrapolation, not a finding.

Mechanistically there is little reason to expect much. Demodex lives inside the follicle
and, in the case of Demodex brevis, inside the sebaceous gland itself. A surface oxidiser
is not well placed to reach an organism sitting that far down in an oil-filled duct. The agents
that do have density data behind them are tiered by strength of evidence in our
research library.

Benzoyl peroxide and benzyl benzoate are not the same thing

This confusion causes real money to be wasted, so it is worth a section of its own.

Benzyl benzoate is an ester that has been used against scabies mites for
decades. It is a direct contact acaricide. A 2025 in-vitro study exposed groups of
Demodex folliculorum to three concentrations and timed them: mean time to death was
26 minutes at 25%, 120 minutes at 10% and 168 minutes at 5%, against 192 minutes for the
immersion-oil control. Only the 25% concentration reached statistical significance, which is
itself worth noting, and the
full methods are on PubMed.

Benzoyl peroxide has none of that. Different molecule, different mechanism,
different literature.

When a forum post claims benzoyl peroxide kills mites, the study being half remembered is
almost always a benzyl benzoate study. The names sit one syllable apart in conversation and
nowhere near each other in the evidence.

Comparison panel of benzoyl peroxide versus benzyl benzoate evidence for Demodex
The two names sit one letter apart in conversation and nowhere near each other in the evidence.

Benzoyl peroxide for rosacea, yeast and fungal acne

There is a genuine yeast angle here, and it is more interesting than the mite one.

Malassezia is the yeast behind fungal acne, dandruff and most facial seborrheic
dermatitis. In a 2026 in-vitro analysis of 17 Malassezia strains, benzoyl peroxide
showed antifungal activity against every species tested, and in susceptible M. furfur
strains it removed fungal viability within eight hours in the dish.

Now hold that against the clinical picture. Malassezia folliculitis is
defined partly by its failure to respond to conventional acne treatment, and
topical benzoyl peroxide is named explicitly in that list. In one series of 26 patients, symptoms
had run for a mean of 61 months and 65% had already been given antibiotics or anti-acne drugs
without benefit.

So the dish and the face disagree, and the face wins. A concentration that works in a well
sits very differently on a living follicle, where the yeast lives below the surface in a lipid
environment and repopulates from an unchanged sebum supply. We unpack that whole pattern in our
guide to Malassezia folliculitis treatment,
and the same logic explains why a
phenotype-based rosacea assessment matters more
than a label.

The practical version: if your bumps are itchy, uniform, sit on the forehead, chest and upper
back, and got worse on antibiotics, benzoyl peroxide for rosacea is not the answer you are looking
for. If your bumps are on the central face with a background of persistent redness, it may well be.

How to use benzoyl peroxide for rosacea without wrecking your barrier

Assume for a moment your clinician has prescribed it and it is the right call. The failures we
see are almost never about the drug and almost always about the routine around it.

Once daily is the dose that was tested. Twice daily was never studied in
rosacea. More is not faster here.

Subtract before you add. Retinoids, acids, scrubs, clay masks and foaming
cleansers all come off the routine first. A stripped barrier is the single most common reason a
rosacea patient cannot tolerate a treatment that would otherwise have worked.

Moisturise around it, not on top of it. A bland moisturiser morning and night,
with the active applied to dry skin, keeps tolerability where the trials found it.

Judge it at twelve weeks, not two. Both trials showed movement by week 2 and
neither had finished improving by week 12. Quitting at three weeks because you are not clear yet
is quitting during the phase where the vehicle arm was also improving.

Expect bleaching. Benzoyl peroxide oxidises fabric dye. Use white towels and
white pillowcases and stop being annoyed about it.

Who benzoyl peroxide for rosacea suits, and who it does not

It suits the patient whose main complaint is bumps: inflammatory papules and
pustules on a centrofacial base, moderate to severe, ideally with a barrier that is intact enough
to take a daily active.

It suits the older patient more than you would guess. In a pooled post-hoc analysis, patients
aged 65 and over reached 60.0% clear or almost clear against 28.1% on vehicle, ahead of the
under-65 group at 45.7% against 23.8%.

It does not suit the patient whose main complaint is a red face with no bumps.
Nothing in this dataset promises you a change in background erythema or in visible vessels, and
starting a strong oxidiser on already-reactive skin to chase a symptom it was not shown to treat
is how people end up worse.

It does not suit skin that is mid-flare from a topical steroid. That situation has its own
rules, set out in our article on
steroid-induced Demodex, and adding an
oxidiser to a rebounding face is rarely the first move.

And it does not, on current evidence, do anything about the mite. If mite density is the driver
in your case, benzoyl peroxide for rosacea is at best a partner to an acaricidal agent, never a
replacement for one. Where the sebum supply itself is the problem, the lever that moves it is
isotretinoin, which is the only common
rosacea drug with published Demodex density data behind it. Relapse behaviour after any
lesion-clearing treatment is covered in our guide to
Demodex maintenance.

For practitioners

Positioning. Encapsulated benzoyl peroxide for rosacea is a lesion-count
drug with a vehicle-controlled evidence base and no anti-parasitic claim. It sits alongside sub-antimicrobial
doxycycline and azelaic acid at steps 2 and 3 of the cascade, not at step 1. Where clinical
suspicion of demodicosis is high, it is an adjunct to an acaricide rather than an alternative.

Evidence quality. Two adequately powered vehicle-controlled phase 3 trials
(n=733) plus a 40-week open-label extension. No comparison against unencapsulated benzoyl peroxide
was performed, so the incremental value of the silica encapsulation is unquantified. The vehicle
response of 16.1% to 25.9% is a useful anchor when interpreting uncontrolled product claims.

Counselling points. Warn about fabric bleaching, set the review point at 12
weeks, and audit the concomitant routine before attributing intolerance to the drug. In patients
whose lesions are monomorphic, pruritic and truncal, consider Malassezia folliculitis
before escalating, since prior failure on benzoyl peroxide is part of that clinical picture rather
than a treatment-resistance signal.

Open question. No Demodex density data exist for this agent in either
direction. A standardised skin surface biopsy before and after a 12-week course would be a small,
cheap and genuinely novel study.

Frequently asked questions

Is benzoyl peroxide for rosacea safe?

In its encapsulated 5% prescription form, yes for most people: 1.8% of trial patients stopped
because of side effects, against 0.4% on the vehicle cream. Conventional over-the-counter benzoyl
peroxide has not been through the same testing in rosacea and is more likely to sting on a
compromised barrier.

Does benzoyl peroxide kill Demodex mites?

There is no published evidence either way. No study has counted mites before and after benzoyl
peroxide. Claims that it does are usually a mix-up with benzyl benzoate, a different molecule with
in-vitro acaricidal data.

How long does benzoyl peroxide for rosacea take to work?

Separation from the vehicle cream appeared at two weeks in both trials, but the results kept
improving through week 12 and again through a 40-week extension. Twelve weeks is the fair point at
which to judge it.

Can I use benzoyl peroxide and ivermectin together?

They act at different points, so combining them is mechanistically sensible, but no trial has
tested the pair and stacking two actives on rosacea-prone skin raises the irritation risk.
Sequence them under supervision rather than starting both in the same week.

Will benzoyl peroxide help the redness in my cheeks?

Not the fixed background redness or the visible vessels. The trial endpoints that moved for
benzoyl peroxide for rosacea were inflammatory lesion counts and overall investigator rating,
which is driven largely by those lesions. Vascular features need a different approach.

Does benzoyl peroxide help fungal acne?

It shows antifungal activity against Malassezia in the laboratory, but Malassezia
folliculitis is clinically characterised by not responding to it. Treat the laboratory result as
interesting and the clinical pattern as decisive.

References

  1. Stein Gold L, Del Rosso JQ, Kircik L, et al. Efficacy and Safety of Microencapsulated Benzoyl
    Peroxide Cream, 5%, in Rosacea: Results From Two Phase III, Randomized, Vehicle-Controlled Trials.
    J Clin Aesthet Dermatol. 2023;16(8):22-29. PMID 37636253.
  2. Draelos ZD, Stein Gold L, Baldwin H, et al. Long-term Efficacy and Safety of Microencapsulated
    Benzoyl Peroxide Cream, 5%, in Rosacea: Results From an Extension of Two Phase III,
    Vehicle-controlled Trials. J Clin Aesthet Dermatol. 2024.
  3. Efficacy and Safety of Microencapsulated Benzoyl Peroxide Cream, 5%, in Papulopustular Rosacea
    in Elderly Patients: Post-hoc Analysis of Results from Two Randomized, Phase III,
    Vehicle-controlled Trials. J Clin Aesthet Dermatol. 2024. PMID 39445322.
  4. Can I, Durdu M. In Vitro Lethal Effects of Benzyl Benzoate Concentrations of 25%, 10%, and 5%
    on Demodex folliculorum Mites: An Experimental Study With a Control Group. J Cosmet Dermatol.
    2025. PMID 40193172.
  5. Malassezia Folliculitis: An Underdiagnosed Mimicker of Acneiform Eruptions. J Fungi. 2025.
    PMC12471122.
  6. Levy A, Feuilhade de Chauvin M, Dubertret L, et al. Malassezia folliculitis: characteristics
    and therapeutic response in 26 patients. Ann Dermatol Venereol. 2007;134(11):823-828. PMID 18033060.
  7. Zhou M, Xie H, Cheng L, Li J. Clinical characteristics and epidermal barrier function of
    papulopustular rosacea. Pak J Med Sci. 2016;32(6):1344-1348. PMC5216279.
  8. In vitro antifungal activity of a fixed-dose clindamycin, adapalene and benzoyl peroxide gel
    against Malassezia species. Presented at the American Academy of Dermatology Annual Meeting, 2026.
  9. Tan J, Almeida LMC, Bewley A, et al. Updating the diagnosis, classification and assessment of
    rosacea: recommendations from the global ROSacea COnsensus (ROSCO) panel. Br J Dermatol.
    2017;176(2):431-438. PMID 27718519.

Not sure whether mites are part of your picture? Start with the
Demodex self-assessment quiz, or browse the full
clinical library. To find a clinician who works
with these conditions, see the practitioner
directory
.

About the author. Marina Ivakhnenko is a
functional skin practitioner who works with Demodex-related skin and eyelid conditions, and
writes the clinical education library at demodex.net/. This article is educational and is not a
substitute for individual medical care. Treatments discussed here are prescription medicines in
most countries and decisions about them belong with your own clinician.

Written by Marina Ivakhnenko — licensed aesthetician, nutritionist and Functional Diagnostic Nutrition Practitioner (FDN-P), with a biology background from Florida Atlantic University. Author of The Demodex Solution.

She works with Ovante, a skincare brand formulating for Demodex-prone, rosacea-prone and folliculitis-prone skin since 1992, and created Rosacea Decoded, a program for rosacea and reactive skin.

Demodex.net is published by the team behind Ovante. Articles here are educational and are not a substitute for care from a physician or dermatologist.

DEMODEX QUIZ

Determine your mite density and get a personalized treatment protocol in 2 minutes.

JOIN OUR COMMUNITY

Connect with 15,000+ members in our private support group.

JOIN OUR COMMUNITY

Latest post

Chronic Inflammation, Demodex & Gut Health, Digestive Triggers, Food Sensitivities, Functional Medicine Evidence, Functional Testing, Gut Dysbiosis, Gut-Skin Axis, Leaky Gut, PubMed Research
Marina Ivakhnenko

●

November 4, 2026

Leaky Gut and Rosacea: What the Evidence Shows, and What to Test Instead

Leaky gut and rosacea: two small zonulin studies, a common
Bacterial vs Demodex, Demodex & Folliculitis, Demodex & Scalp Folliculitis, Demodex vs Folliculitis, Dermoscopy, Fungal vs Demodex, Itchy Scalp, Recurrent Folliculitis, Scalp Bumps, Scalp Symptoms, Severe Scalp Inflammation, Shampoo Protocols, Sulfur
Marina Ivakhnenko

●

November 4, 2026

Scalp Folliculitis: Nine Causes That Look the Same, and How to Tell Yours Apart

Scalp folliculitis is a pattern with at least nine causes.
Azelaic Acid, Clinical Trials, Demodex & Rosacea, DEMODEX & SKIN CONDITIONS, Demodex Diagnosis & Testing, Dermatology Studies, Dermoscopy, Ivermectin, Metronidazole, Papulopustular Rosacea, Persistent Redness, Prescription Therapies, Research & Clinical Studies, RESEARCH & SCIENCE, Rosacea Maintenance, Rosacea Relapse, Symptoms & Clinical Signs, SYMPTOMS & SIGNS, TESTING & DIAGNOSIS, Topical Therapies, TREATMENT & PROTOCOLS, Treatment Protocols
Marina Ivakhnenko

●

September 28, 2026

Ivermectin vs Metronidazole for Rosacea: Who Wins, and Who Needs Which

Ivermectin vs metronidazole is not a simple win. The head-to-head
Demodex & Autoimmune Conditions, Demodex & Immune Dysregulation, Demodex & Seborrheic Dermatitis, DEMODEX & SKIN CONDITIONS, Demodex Diagnosis & Testing, Demodex vs Contact Dermatitis, Demodex vs Seborrheic Dermatitis, Differential Diagnosis, Facial Symptoms, Functional Testing, Prescription Therapies, Skin Scraping, Symptoms & Clinical Signs, SYMPTOMS & SIGNS, TESTING & DIAGNOSIS, TREATMENT & PROTOCOLS, Unexplained Inflammation
Marina Ivakhnenko

●

September 28, 2026

Dupilumab Facial Redness: Yeast, Mite, or Something Else?

Dupilumab facial redness is not one condition. Yeast, Demodex mites,
Burning & Stinging, Chronic Failed Treatment, Demodex & Autoimmune Conditions, Demodex & Chronic Inflammation, Demodex & Perioral Dermatitis, Demodex & Rosacea, DEMODEX & SKIN CONDITIONS, FAQS & QUICK ANSWERS, Papulopustular Rosacea, Persistent Redness, Prescription Therapies, Red Flags & Doctor Referral, Rosacea Flushing, Rosacea Recovery, Rosacea Relapse, Steroid Rebound, Steroid-Induced Demodex, Symptoms & Clinical Signs, SYMPTOMS & SIGNS, Topical Therapies, TREATMENT & PROTOCOLS, Treatment Protocols
Marina Ivakhnenko

●

September 8, 2026

Steroid Induced Rosacea: Why the Cream That Worked Is the Reason It Will Not Stop

Steroid induced rosacea is not the steroid masking a condition.
Chronic Perioral Flares, Demodex & Perioral Dermatitis, DEMODEX & SKIN CONDITIONS, Demodex vs Perioral Dermatitis, Differential Diagnosis, Facial Symptoms, Itchy Perioral Rash, Mouth Rash, Nose Fold Irritation, Persistent Redness, POD vs Rosacea, Prescription Therapies, Redness Around Mouth, Steroid Rebound, Symptoms & Clinical Signs, SYMPTOMS & SIGNS, TESTING & DIAGNOSIS, Topical Therapies, TREATMENT & PROTOCOLS, Treatment Protocols
Marina Ivakhnenko

●

September 8, 2026

Perioral Dermatitis Treatment: Why the Best Evidence Is for Stopping, Not Starting

The best-supported perioral dermatitis treatment is removing things, not adding